Introduction
Mesenchymal stem cells (MSCs) are progenitor cells with capacity of self-renewal, multilineage differentiation, and immunomodulation. Emerging experimental and clinical evidence has shown that systemic infusion of MSCs results in significant immunosuppressive effects in terms of treating a variety of inflammatory and autoimmune diseases by inhibiting the proliferation and function of immune cells, including dendritic cells, T and B lymphocytes, and natural killer (NK) cells [1] [2] [3] . The immunomodulatory properties of MSCs are associated with direct cell-cell contact with T cells or/and production of a variety of cytokines and chemokines, such as interleukin 10 (IL-10), nitric oxide (NO), indoleamine 2, 3-dioxygenase (IDO), prostaglandin E2 (PGE2), transforming growth factor β (TGF-β), tumor necrosis factor-inducible gene 6 (TSG-6), and chemokine (C-C motif) ligand 2 (CCL2) [1, 2, [4] [5] [6] [7] [8] . These cytokines and chemokines contribute to the consequent regulation of CD4 + CD25 + Foxp3 + regulatory T (Treg) cells and proinflammatory T helper 17 (Th17) cells, balancing the host immune homeostasis [8] [9] [10] .
Although it is well known that MSCs possess immunosuppressive effect, it is unclear whether all MSC subsets have an equal degree of immunosuppression. Recently, several reports showed that engagement of different Toll-like receptors (TLRs) in MSCs either enhanced or inhibited their immunosuppressive properties [11] [12] [13] . mostly immunosuppressive ones [12] . Furthermore, NO and IDO were reported to act as a switch in determining MSC-based immunosuppression or enhancing immune response [14] . The accumulated evidence suggests that MSCs may possess variable immunoregulatory function, but the detailed mechanism is unknown.
Interleukin-17 (IL-17), a proinflammatory cytokine, has critical roles in the pathogenesis of autoimmune diseases, such as rheumatoid arthritis, psoriasis, inflammatory bowel diseases, diabetes, and multiple sclerosis [15] . IL-17 also contributes to host defense against extracellular and intracellular pathogens, including Aspergillus fumigatus, Cryptococcus neoformans and Candida albicans (C. albicans) [16, 17] . In addition to CD4 + Th17 cells, a variety of T cells, including CD8 + T cells (Tc17), γδT cells, natural killer T (NKT) cells, innate immune cells, macrophages, and paneth cells, have the capacity to produce IL-17 [18] [19] [20] [21] . It was reported that Foxp3 + /IL-17 + Tregs lose their immunosuppressive function due to production of IL-17 [22] . In this study, we identify a new subset of IL-17 + MSCs capable of inhibiting C. albicans growth and attenuating cell-based immunosuppression.
Results

Identification of IL-17
+ bone marrow MSCs To examine whether MSCs contain a subset of cells expressing IL-17, we used western blot and ELISA analysis to show that culture expanded human (h) and mouse (m) MSCs expressed IL-17 ( Figure 1A and 1B). hMSCs and mMSCs expressed CD146 and Sca1, but not T cell markers CD3, CD4, CD8a and hematopoietic stem cell marker CD34, as assessed by western blot ( Figure 1A ) and flow cytometric analysis (Supplementary information, Figure S1 ). The secretion of IL-17 to the culture medium was detectable by ELISA assay ( Figure 1C ). Immunofluorescent and immunocytochemical staining also showed that hMSCs expressed IL-17, but not T cell markers CD3, CD4 and CD8a. Activated human peripheral blood mononuclear cells (hPBMCs) were used as a positive control ( Figure 1D Figure 1F ). Recent study showed that MSCs promoted Th17 cell expansion through activating caspase 1 when co-culturing with activated T cells or PBMCs [23] . To exclude the possibility of IL-17 produced by T cell contamination in MSC population, CD3 antibody/complement treatment was used to deplete potential contaminated T cells in MSC cultures (Supplementary information, Figure S3 ). qPCR analysis showed that Sca1 + IL-17 + MSCs expressed similar level of IL-17 mRNA after CD3 antibody/complement treatment. Western blot and ELISA analysis also showed that T cell depletion did not affect expression levels of IL-17 in hMSCs ( Figure 1G and 1H). Since combinatorial cytokine treatment, such as IL-6, TGF-β1, IL-1β and IL-23, stimulated Th17 polarization and IL-17 secretion [24, 25] , we examined whether such cytokine treatment would alter IL-17 expression in MSCs. After treating with a variety of combinatorial cytokines, we found that IL-1β and IL-6 treatment was capable of upregulating the number of IL-17 + MSCs and IL-17 secretion to the culture medium, as assessed by flow cytometric analysis and ELISA (Supplementary information, Figure S4A and S4B). Additionally, IL-1β and IL-6 treatment elevated IL-17 expression, as assessed by qPCR and western blot analysis (Supplementary information, Figure S4C and S4D). It was reported that transcription factor retinoid orphan receptor γ T (RORγt) regulated IL-17 expression via signal transducer and activator of transcription 3 (Stat3) [26, 27] . Therefore, we measured the expression levels of Stat3 and RORγt in IL-1β and IL-6-treated MSCs and found that IL-1β and IL-6 treatment elevated IL-17 expression, along with increased p-Stat3 and RORγt, as assessed by western blotting analysis (Supplementary information, Figure S4D ). When MSCs were pretreated with 5, 15-DPP, a selective Stat3 inhibitor, IL-1β and IL-6-induced upregulation of IL-17 and RORγt was blocked (Supplementary information, Figure S4E ). Collectively, these data indicate that MSCs contain a unique subset of IL-17 + cells and that IL-1β and IL-6 treatment elevated the number of IL-17 + MSCs through Stat3 and RORγt signaling.
Single colony-derived IL-17 + MSCs showed compromised immunosuppressive capacity
Since MSCs are a heterogeneous population containing multiple colony clusters, we confirmed that part of single colony-derived MSCs express IL-17. Fluorescent immunocytostaining showed that a small fraction (3.33%) of single colonies was positive for IL-17 antibody staining ( Figure 2A ). Next, we performed ELISA assay and selected three IL-17 + (#2, #3 and #4) and three IL-17 -(#1, #5 and #6) single colony-derived MSCs ( Figure 2B ). Western blot analysis confirmed that the IL-17 + colonies expressed a significantly higher level of IL-17 than IL-17 -colonies ( Figure 2C ). IL-17 + (#2, #3 and #4) MSCs were positive for CD146 and Sca1, but negative for CD3, CD4, CD8a and CD34, as assessed by flow cytometric analysis (Supplementary information, Figure S5 ). T cell depletion with CD3 antibody/complement treatment Figure 2D ) and ELISA analysis ( Figure 2E ). Single colony-derived MSCs may show variable stem cell properties, including proliferation and multipotent differentiation [28] . We showed that all selected single colony-derived MSCs were capable 
IL-17
-T cells were used as positive and negative controls, respectively. (G, H) Western blot and ELISA analysis showed that CD3 antibody/complement treatment did not affect IL-17 expression in hMSCs. ** P < 0.01 and *** P < 0.001 (mean ± SD). Scale bar, 25 μm. The data are representative of three independent experiments. Figure  S6C ). These results confirmed the stem cell properties and heterogeneity of these single colony-derived MSCs [28] . IL-17 is a proinflammatory cytokine capable of promoting inflammation by inducing various proinflammatory cytokines and chemokines [29] . Since MSCbased immunomodulation is associated with upregulation of Tregs and downregualtion of Th17 cells [8] [9] [10] , we examined whether IL-17 + MSCs were able to regulate Tregs and Th17 cells in a T cell/MSC co-culture system. www.cell-research.com | Cell Research Figure 3A ) [30, 31] . Oral administration of 3% DSS for 10 days induced acute colitis in C57BL/6 mice, as characterized by an overall elevation of disease activity index (DAI) based on the presence of sustained weight loss and bloody diarrhea/ loose feces [9, 31] . Bulk and single colony-derived MSCs (#1-#6) were systemically infused into experimental colitis mice on day 3 post 3% DSS induction ( Figure  3A ). Bulk and IL-17 -MSC infusions (#1, #5 and #6), but not IL-17 + MSC (#2, #3 and #4) infusion, significantly reduced DAI and levels of Th17 cells and IL-17, along with elevated levels of Tregs and IL-10 ( Figure 3B-3F ). In addition, bulk and IL-17 -MSC (#1, #5 and #6) infusion significantly ameliorated colonic transmural inflammation and suppressed mucosal ulceration, thus restoring normal intestinal structure and resulting in a reduced histological index, but IL-17 + MSC (#2, #3 and #4) infusion failed to restore normal intestinal structure ( Figure 3G and 3H). These data together confirm that IL-17 + MSCs have compromised immunomodulatory function.
+ MSCs showed reduced TGF-β1 expression To examine whether IL-17 directly contributes to compromised immunoregulation in IL-17 + MSCs, we used small interfering (si) RNA to knockdown IL-17 expres- . Expression levels of TNF-α and IFN-γ were too low to be detected in MSCs (data not shown). However, the levels of TGF-β1 secretion and expression were significantly reduced in IL-17 + MSCs compared to bulk and IL-17 -MSCs, as assessed by ELI-SA and qPCR, respectively ( Figure 4G and 4H). Using neutralizing antibody treatment, we next verified that the inhibition of TGF-β1 in MSCs reduced the capacity of MSCs to upregulate Tregs ( Figure 4I ) and downregulate Th17 cells ( Figure 4J ). These findings suggest that reduction in TGF-β1 production may play a critical role in reduced immunosuppression of IL-17 + MSCs.
IL-17 inhibited TGF-β1 expression via activation of NFκB pathway
To verify the functional role of IL-17 in MSC-based immunomodulation, we used IL-17 to treat bulk MSCs and IL-17 -MSCs (#5), and found that IL-17 treatment induced a significant reduction in MSC-mediated upregulation of Tregs and downregulation of Th17 cells compared to untreated control group ( Figure 5A and 5B). Next, we examined whether IL-17 contributed to the decreased TGF-β1 expression in MSCs. ELISA and qPCR analysis showed that IL-17 treatment downregulated TGF-β1 expression in bulk and IL-17 -MSCs (#5) ( Figure 5C and 5D ). This downregulated TGF-β expression could be reversed by knockdown of IL-17 receptor (IL-17R) expression by siRNA ( Figure 5E , 5F and Supplementary information, Figure S7 ). Since IL-17 activates several signaling pathways, including nuclear factor (NF) κB pathway, extracellular signal-regulated kinase (ERK), JNK, Stat3 and p38 pathways, to induce proinflammatory cytokine and chemokine production [21] , we performed western blot analysis and showed that IL-17 treatment induced phosphorylation of p65, IκBα, ERK and Stat3, but not p38 and JNK, in MSCs (Supplementary information, Figure S8 ). To identify the specific pathway that may contribute to IL-17-mediated reduction of TGF-β1 expression, we used specific inhibitors to effectively block IL-17 downstream pathways (Supplementary information, Figure S8 ). Subsequently, ELISA and qPCR analysis showed that IκB kinase (IKK) inhibitor VII (inhibition of NFκB-mediated gene expression), but not Stat3 (5, 15-DP) or Erk (PD325901) inhibitor rescued TGF-β1 expression in IL-17-treated MSCs ( Figure 5G and 5H). Knockdown of IKKα by siRNA to block IκBα degradation (inhibition of NFκB-mediated gene expression; IKKα siRNA: sc-29365, Santa Cruz Biotechnology, Santa Cruz, CA, USA) also blocked IL-17-induced downregulation of TGF-β1 in MSCs (Figure 5I, 5J and Supplementary information, Figure S7 ), suggesting that the NFκB pathway may play a critical role in IL-17-mediated downregulation of TGF-β1. To determine how NFκB regulates TGF-β1 expression in MSCs, NFκB-binding consensus sequence in TGF-β1 promoter region was examined by chromatin immunoprecipitation (ChIP) with NFκB-specific antibody, followed by qPCR assay using a primer pair designed near the predicted site. Of the three putative binding sites, one NFκB-binding DNA sequence was significantly enriched in IL-17-treated MSCs ( Figure 5K ). Luciferase assay showed that TGF-β1 promoter activity was inhibited by IL-17 treatment, which could be rescued by IL-17R and IKKα siRNAs ( Figure 5L ). To further verify the role of IL-17 in inhibiting MSC-based immunomodulation via the NFκB pathway, we used IKK inhibitor VII to block IL-17-activated NFκB signaling and found that IKK inhibitor VII treatment enabled IL-17-treated MSCs to upregulate Tregs and downregulate Th17 cells ( Figure 5M  and 5N ). These findings indicate that IL-17 blocks MSC immunosuppressive function via IL-17R/ NFκB/TGF-β1 signaling (Supplementary information, Figure S9 ).
IL-17
+ MSCs inhibited C. albicans growth Previous studies indicated that IL-17 possessed anti-C. albicans effect [32] . To examine whether MSCs, especially IL-17 + MSCs, have anti-C. albicans effect, we cocultured MSCs with C. albicans for 6 h and showed that MSCs and conditional medium (CM) significantly inhibited C. albicans growth compared to the control medium. It appeared that MSCs showed more significant inhibition of C. albicans growth than CM ( Figure 6A ). These data suggest that anti-C. albicans effect of MSCs is partially associated with soluble secreted factors. Next, we compared anti-C. albicans activity of IL-17 + and IL-17 -MSCs and found that IL-17 + MSCs (#2 and #3) showed increased anti-C. albicans effect compared to IL-17 -and bulk MSCs (#5 and #6; Figure 6B ). To confirm that IL-17 directly inhibited C. albicans, we added recombinant IL-17 to cultured C. albicans and found that IL-17 inhibited C. albicans growth in a dose-dependent manner ( Figure  6C ). Anti-IL-17 neutralizing antibody could partially reduce MSC-mediated anti-C. albicans activity in compari- 
IL-17 + MSCs showed increased therapeutic effects in mice infected with C. albicans
To further determine the anti-C. albicans effect of IL-17 + MSCs, we infected C57BL/6 mice with 2 × 10 5 CFU of C. albicans ( Figure 7A ). One day after C. albicans injection, mice were treated with 1 × 10 6 single colonyderived MSCs. The extent of candidiasis was examined on day 7 post-MSC infusion by evaluating body weight alteration, kidney fungal burden, ratio of CD4 + IL-17 + cells and histology. The body weight of mice infected with C. albicans was significantly reduced compared to the control C57BL/6 mice on days 3 to 7 post-infection. After MSC infusion, body weight was more significantly increased in IL-17 + MSC treatment group than that of bulk and IL-17 -MSC groups ( Figure 7B ). Although bulk and IL-17 -MSC infusion groups showed some degree of reduction of total C. albicans counts in kidney, the IL-17 + MSC infusion group showed a more significant fungal clearance ( Figure 7C ). IL-17 + MSC infusion, but not bulk or IL-17 -MSC infusion, elevated the level of Th17 cells, which may play an additional role in anti-C. albicans growth ( Figure 7D 
Discussion
Previous studies indicate that MSC-based immunotherapy is a promising therapeutic approach for a variety of autoimmune diseases, including systemic sclerosis and systemic lupus erythematosus [1, 6, 8, 33] . However, the detailed mechanism of MSC-based immune therapy is not fully elucidated [34] . Although many types of MSC surface molecules were identified and some subpopulations could be isolated according to the surface markers [35] , no specific functional MSC subpopulation has ever been successfully characterized, presenting a significant obstacle to the development of an effective MSC-based therapy. Thus, it is necessary to study the heterogeneity of MSCs to identify their different functional subsets. The aim of this study is to examine whether MSCs contain a novel subset of MSCs that produce functional IL-17. IL-17 is mainly produced by immune cells, such as Th17 and γδ T cells [21] + MSC infusion group showed a significantly more effective clearance of C. albicans infiltration compared to bulk and IL-17 -MSC groups, as viewed by PAS staining. * P < 0.05; ** P < 0.01; and *** P < 0.001 (mean ± SD). Scale bars, 50 μm. The data are representative of three independent experiments.
www.cell-research.com | Cell Research [21] . We identified that IL-17 is capable of inhibiting TGF-β1 production in MSCs via the NFκB pathway. Since TGF-β1 plays a critical role in MSC-based immunomodulation by governing the levels of Tregs and Th17 cells [36] [37] [38] , reduced TGF-β1 expression in IL-17
+ MSCs results in abolishment of MSC-mediated immunosuppression. The decreased TGF-β1 production in IL-17 + MSCs can also be rescued by knockdown of IL-17 expression. Moreover, inhibition of the NFκB pathway by a chemical inhibitor or IKKα siRNA could recover TGF-β1 production, confirming that IL-17 regulates TGF-β1 production via the NFκB pathway. Additionally, we reveal that NFκB directly binds to the TGF-β1 promoter region to regulate TGF-β1 expression. These data imply that IL-17/NFκB/TGF-β1 signaling contributes to the impaired immunosuppressive function in IL-17 + MSCs. Finally, fungus infection is frequently associated with reduced host immune activity. However, it appears that MSC-mediated immunosuppression may not increase the risk of fungus infection in the recipients [39] . It is well known that IL-17 provides host defense against extracellular pathogens and possesses anti-fungal effect [40] . Interestingly, similar to the IL-17 produced by Th17 cells, we found that MSC-produced IL-17 possesses antifungal effect. IL-17 + MSC infusion further increased Th17 levels in C. albicans-infected mice. This may explain why MSC infusion does not result in fungal infection. In this study, we showed that sorted Sca1 Although the mechanism by which IL-17 + MSCs upregulate Th17 cells is unknown, the interplay between donor MSCs and recipient microenvironment may determine MSC-based immunomodulatory response [33, 41] . Our findings imply that MSC-based immunomodulation is regulated by different subsets of MSCs, in which they may exert either immunosuppressive or immunostimulatory functions. Previous studies showed that MSCs possess anti-bacterial effects via secretion of anti-microbial peptide LL-37 [42] . Our results indicate that MSCs are able to antagonize fungus infection, suggesting that MSCs may serve as a defense barrier against microbe invasion. Existence of IL-17 + MSCs may counterbalance the immunosuppressive role of MSCs under infection situation. Furthermore, understanding functional roles of different MSC subpopulations will facilitate to maximize the therapeutic effects for inflammatory and autoimmune diseases. As an alternative strategy, purified subsets of IL-17 -MSCs may offer improved therapeutic effects for immune diseases.
In conclusion, we identify a novel subpopulation of IL-17 + MSCs that inhibit C. albicans growth, but fail to execute MSC-based immunosuppression as a result of reduced TGF-β1 expression. These findings suggest that MSCs contain different functional subpopulations with correspondingly unique therapeutic functions.
Materials and Methods
Mice
Female C57BL/6J mice were purchased from the Jackson Lab (Bar Harbor, ME, USA). All animal experiments were performed under the institutionally approved protocols for the use of animal research (USC #10941 and 11327, and Peking University # LA2012-65).
Antibodies
Anti-CD4-PerCP, CD25-APC, Sca1-PE, CD146-PE, CD3ε, PE-CD34, APC-CD3, PE-CD8a and CD28 antibodies were purchased from BD Biosciences (Franklin Lakes, NJ, USA). Anti-Foxp3-PE, IL-17-APC, and IL-17-PE antibodies were purchased from eBioscience (San Diego, CA, USA). Unconjugated antibodies to IL-17 and RORγt were purchased from Millipore Corporation (Bedford, MA, USA) and Abcam (Cambridge, MA, USA). Unconjugated antibodies to p-Stat3, Stat3, p-ERK, ERK, p-p38, p38, p-JNK, JNK, p-p65 and p65 were purchased from Cell Signaling Technology (Danvers, MA, USA). LEAF™ Purified human specific IL-17 and TGF-β1 antibodies were purchased from BioLegend (San Diego, CA, USA). Unconjugated antibody to ALP and goat isotype control antibody were purchased from Santa Cruz Biotechnology. Anti-rat IgG-rhodamine antibody was purchased from Southern Biotech (Birmingham, AL, USA). Hybridoma (38.1) for human CD3 mAb was purchased from ATCC (Manassas, VA, USA). Antirabbit IgG-AlexaFluor 488 antibody was purchased from Invitrogen Corporation (Carlsbad, CA, USA). Anti-β-actin antibody, inhibitors for Stat3 (5, 15-DPP), ERK (PD325901), JNK (SP600125), IKK inhibitor VII and p38 inhibitor (SB203580) were purchased from Sigma-Aldrich (St. Louis, MO, USA).
Isolation of mouse bone marrow MSCs
Bone marrow cells were flashed out from bone cavity of fe- murs and tibias with 2% heat-inactivated fetal bovine serum (FBS; Equitech-Bio, Kerrville, TX, USA) and cultured with α minimum essential medium (α-MEM, Invitrogen) supplemented with 20% FBS, 2 mM L-glutamine (Invitrogen), 55 μM 2-mercaptoethanol (Invitrogen), 100 U/ml penicillin, and 100 μg/ml streptomycin (Invitrogen), as previously reported [43] .
Human bone marrow MSCs culture
Human bone marrow aspirates from healthy adult donors (20-35 years of age) were purchased from AllCells (Emeryville, CA, USA). Human bone marrow progenitor cells were enriched using fresh human bone marrow by RosetteSep® Human Bone Marrow Progenitor Cell Pre-Enrichment Cocktail (STEMCELL Technologies, Vancouver, BC, Canada) following the manufacturer's instructions. The enriched single-cell suspensions were cultured with α-MEM supplemented with 15% FBS, 100 mM L-ascorbic acid-2-phosphate, 2 mM L-glutamine, 100 U/ml penicillin, and 100 μg/ml streptomycin and passaged, as previously reported [44] .
Isolation of single colony derived-human MSCs from single cell
For isolation of single colony-derived MSCs, the enriched single-cell suspensions were plated at about 50-100 cells per 10 cm dish under 37 °C at 5% CO 2 condition for 1-2 weeks and examined with an inverted microscope twice a day. The colonies were picked up using a Pyrex ® cloning cylinder (Sigma-Aldrich) when they reached optimal size (50-100 cells in each colony). Single colony was derived from one cell.
Cell proliferation assay
Single colony-derived MSCs were passaged to 4-well chamber slides (Nunc, 1 × 10 4 per well) and incubated for 12 h under 37 °C at 5% CO 2 condition. Then the cells were assayed for bromodeoxyuridine (BrdU) incorporation, as described previously [45] .
Osteogenic differentiation assay
Single colony-derived MSCs were cultured under osteogenic culture condition medium containing 1.8 mM KH 2 PO4 and 10 nM dexamethasone (Sigma-Aldrich). After 28 days of osteogenic induction, the cultures were stained with Alizarin Red. Expression of the osteogenic marker ALP was assayed by western blot analysis.
Adipogenic differentiation assay
Single colony-derived MSCs were cultured under adipogenic culture condition medium containing 0.5 mM Isobutylmethylxanthin (Sigma-Aldrich), 60 μM Indomethacin (Sigma-Aldrich), 0.5 μM Hydrocortisone (Sigma-Aldrich), and 10 μg/ml insulin (Sigma-Aldrich). After 14 days of adipogenic induction, the cultures were stained with Oil Red O. Expression of the adipogenic lineage-specific genes LPL and PPARγ was assayed by semiquantitative PCR.
Immunofluorescent staining
MSCs were seeded on a 4-well chamber slide and incubated for 12 h under 37 °C at 5% CO 2 condition. Then the slides were fixed in 4% paraformaldehyde, followed by 0.01% Triton-100 treatment for 10 min. The slides were blocked with normal serum matched to secondary antibodies for 1 h, followed by incubation with the specific or isotype-matched antibodies (1:100) overnight at 4 °C. 
T lymphocyte isolation
Human PBMCs were purchased from AllCells. Human naïve T lymphocytes were purified by negative selection from PBMCs using a Pan T cell isolation kit (Miltenyi Biotec, Auburn, CA, USA), according to the manufacturer's instructions.
Tregs and Th17 cells co-cultured with MSCs
Human naïve T lymphocytes (1 × 10 6 per well) were precultured on 24-well multiplates under Dulbecco's Modified Eagle's Medium (DMEM, Lonza) with 10% heat-inactivated FBS, 50 μM 2-mercaptoethanol, 10 mM HEPES (Sigma-Aldrich), 1 mM sodium pyruvate (Sigma-Aldrich), 1% nonessential amino acid (Lonza Inc, Allendale, NJ, USA), 2 mM L-glutamine, 100 U/ml penicillin and 100 mg/ml streptomycin in the presence of plate-bound anti-CD3ε antibody (2 μg/ml) and soluble anti-CD28 antibody (2 μg/ ml) for 2-3 days. For Treg differentiation, recombinant human TGF-β1 (2 ng/ml) (R&D Systems, Minneapolis, MN, USA) and IL-2 (2 ng/ml) (R&D Systems) were added. For Th17 induction, recombinant human TGF-β1 (2 ng/ml) and IL-6 (50 ng/ml) (R&D Systems) were added. IL-17 
CD3 + T cell depletion by antibody/complement treatment
To deplete CD3 + T cells, 1 ml predetermined proper concentration of CD3 mAb (Hybridoma: 38.1, ATCC) was added to hPBMCs and hMSCs (1 × 10 7 ) and incubated for 30 min at 4 °C. The cells were centrifuged for 5 min to remove unbound antibody and discard supernatant. Then the pellets were resuspended in 1 ml (1:6) diluted rabbit complement (Pel-Freez Biologicals, Rogers, AR) and incubated for 30 min at 37 °C. The cells were centrifuged for 5 min to remove unbound complement and discard supernatant. One round of treatment with cytotoxic antibody/complement was repeated. Isotype IgM was used as a negative control. The efficacy of T cell depletion was determined by flow cytometric analysis. hMSCs were cultured for 3 days for IL-17 expression analysis [46] .
Flow cytometry analysis
The following antibodies were used for surface staining: antimouse Sca1-PE, mouse CD4-Percp, mouse CD25-APC, human CD4-Percp, human CD3-APC, human CD8a-PE, human CD34-PE and human CD25-APC. For intracellular cytokine or transcription factor expression, staining was performed using Foxp3 staining buffer according to the manufacturer's instructions (eBioscience). Anti-mouse Foxp3-PE, mouse IL-17-APC or -PE, human Foxp3-PE, and human IL-17-APC or -PE were used for intracellular 
Western blot
Cells were lysed in M-PER ® mammalian protein extraction reagent (Pierce). 20 μg of total proteins were applied and separated on 4%-12% NuPAGE ® gel (Invitrogen) and transferred to Immobilon™-P membranes (Millipore Corporation). The membranes were blocked with 5% non-fat dry milk and 0.1% Tween 20 for 1 h, followed by incubation with the primary antibodies (1:100-1 000 dilution) at 4 o C overnight. Then they were treated with horseradish peroxidase-conjugated rabbit or mouse IgG (Santa Cruz) (1:10 000) for 1 h, enhanced with a SuperSignal ® West Pico Chemiluminescent Substrate (Pierce, Rockford, IL, USA), and exposed to BIOMAX MR films (Kodak, Rochester, NY, USA).
Semi-quantitative PCR and real-time PCR
For semi-quantitative PCR and real-time PCR (qPCR) analyses, total RNA was extracted with RNeasy Mini kit (Qiagen, Valencia, CA, USA), and cDNA was prepared using a SuperScript ® III Reverse Transcriptase (RT) kit (Invitrogen). Semi-quantitative PCR was performed using gene-specific primers (Supplementary information, Table S1 ) and Platinum ® PCR SuperMix (Invitrogen). The amplified PCR products were separated by 2% agarose gels with ethidium bromide and visualized by UV light. qPCR was carried out using SYBR ® Green Supermix (Bio-Rad) on a Bio-Rad CFX96 Real Time system, as indicated by the manufacturer's protocol. The level of mRNA expression for each gene was normalized to GAPDH mRNA expression.
ELISA
Peripheral blood was collected from the retro-orbital plexus of mice and centrifuged to obtain the blood serum. Culture supernatants from MSCs were collected. MSCs were extracted using M-PER ® mammalian protein extraction reagent. The samples were centrifuged and used for IL-17 (BioLegend), IL-10, IL-6, TNF-α, IFN-γ, PGE2 and TGF-β1 (R&D Systems) ELISA analysis.
Chromatin immunoprecipitation assay
Cells were fixed, nuclei were lysed, and chromatin was sheared with a Branson sonicator. Immunoprecipitation was performed with the Millipore ChIP kit according to the manufacturer's protocol. To precipitate NFκB complexes, NFκB antibody was used and goat IgG was used as an isotype control. Percentage input was determined by removing an aliquot of sheared chromatin prior to immunoprecipitation and comparing amplification of this DNA with amplification of the precipitated chromatin. Putative NFκB-binding sites in TGF-β1 promoter regions were investigated to assay the relative enrichment by qPCR. Primers are listed in Supplementary information, Table S1 .
Luciferase assay
TGF-β1 promoter region was PCR amplified from MSC genomic DNA and inserted into pGL3 vector by HindIII and XhoII to construct the reporter plasmid. MSCs on a 24-well plate were transiently transfected with TGF-β1-luciferase plasmid and renilla luciferase plasmid at the ratio of 10:1. After 24 h of transfection, cells were collected, and luciferase activity was measured with a dual-luciferase reporter assay kit (Promega). All data were normalized to renilla luciferase activity.
MSC infusion into acute colitis mice
Acute colitis was induced by administering 3% (w/v) dextran sulfate sodium (DSS, molecular mass 36 000-50 000 Da; MP Biochemicals, France) through drinking water, which was fed ad libitum for 10 days. Bulk MSCs and single colony-derived MSCs were infused (1 × 10 6 cells) into colitis mice (n = 6) intravenously on day 3 after feeding DSS water. In the control group, mice received PBS (n = 6). Samples from all mice were harvested on day 10 after feeding DSS water. Induced colitis was evaluated as previously described [30, 31] .
C. albicans culture and anti-fungal activity assays C. albicans (ATCC ® MYA-2876 TM ) was grown overnight at 37 °C in liquid Luria-Bertani (LB) medium (Difco BD, Sparks, MD, USA) with slight agitation and harvested by centrifugation. The pellet was resuspended and centrifuged. The density of inoculum was adjusted to 1.0 at A 600 nm , corresponding to 5 × 10 6 -1 × 10 7 CFU/ml, as determined by serial dilution and colony counts. Inhibition of C. albicans growth by MSCs and CM was assessed by counting CFU. Briefly, MSCs plated in 24-well plates (3 × 10 4 hMSCs and 2 × 10 5 mMSCs per well) were infected with 500 CFU of C. albicans and incubated for 6 h under 37 °C at 5% CO 2 condition. Then the plates were vigorously shaken, and aliquots of culture medium were taken from each well and serially diluted with sterile PBS and plated on LB-agar plates at 37 °C. Colonies were counted the next day. Anti-C. albicans activity of MSC CM (or hIL-17A) was subjected to a susceptibility test, according to a previous report [42] , with slight modifications. Briefly, CM was obtained from three-day cultured hMSCs and mMSCs by passing through a 0.22 μm filter (Millipore). The aliquots (380 μl) were transferred to a 24-well plate, inoculated with 500 CFU of C. albicans (in 20 μl of PBS) and incubated for 6 h at 37 °C. Then CFUs were analyzed as described earlier. To further evaluate anti-C. albicans activity of IL-17, MSCs were preincubated with IL-17 neutralizing antibody or isotype control antibody for 2 h, then added to 500 CFU of C. albicans and incubated for 6 h for CFU analysis.
MSC infusion into mice infected with C. albicans
C57BL/6 mice were infected intravenously with 2 × 10 5 C. albicans and then monitored daily. Bulk MSCs and single colonyderived MSCs (1 × 10 6 cells) were intravenously infused into infected mice (n = 6) 1 day after induction of C. albicans. In the control group, mice received PBS (n = 6). Samples from all mice were harvested on day 7 after infection. For fungal burden analysis, kidneys were removed, weighed and dissected to cell suspension, then serially diluted with sterile PBS and plated on LB-agar plates at 37 °C for CFU counting. For histological analysis, kidney samples were stained with PAS or hematoxylin and eosin.
Statistical analysis
P-values were analyzed from two-tailed Student's t-test or one-way analysis of variance using SPSS 13.0 software. P-values less than 0.05 were considered statistically significant.
